All In Biotech

Drug Trial Radar · NCT01436994

Antithyroid Drug Treatment of Thyrotoxicosis in Young People

A Randomised Study of Two Anti-thyroid Drug Treatment Regimens in Young People

Last checked: Nov 20, 2026Latest source record: Sep 21, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

81

Actual

Start

Jul 2004

Primary completion

Dec 2014

Study completion Nov 2015

Sponsor

Lead sponsor
Newcastle-upon-Tyne Hospitals NHS TrustAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 20, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 2 years, up to 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The investigators aim to establish whether biochemical control during anti-thyroid drug therapy in young people with thyrotoxicosis varies depending upon whether a 'block and replace' or 'dose titration' regimen is used. The investigators will also assess remission rates and the frequency of side-effects in the two treatment groups.

Conditions

  • Paediatric Thyrotoxicosis

Interventions

  • Block and ReplaceProcedure

    The primary objective of treatment is to maintain a euthyroid state with TSH and thyroid hormone levels in the local laboratory normal range. Carbimazole is commenced in a dose of 0.75 mg/kg/day (propylthiouracil - for dose see below) with the aim being to completely preventing endogenous thyroxine production. Thyroxine is then added in a low replacement dose as the thyroid hormone levels fall into the lower half of the laboratory normal range. The principle measure of control during the first 6 months will be thyroid hormone levels rather than TSH. Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil.

  • Dose TitrationProcedure

    The primary objective of treatment is to maintain a euthyroid state with TSH and thyroid hormone levels in the local laboratory normal range. Carbimazole is commenced in a dose of 0.75 mg/kg/day until thyroid hormone levels fall into the local laboratory normal range. The dose is then reduced to 0.25 mg/kg/day with the intention of maintaining a euthyroid state as reflected by a free thyroxine and TSH within the normal range. Most paediatricians in the UK commence thyrotoxic children on carbimazole rather than propylthiouracil. Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. The guidelines detailed above can be used in the knowledge that 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil.

  • carbimazoleDrug

    Carbimazole 5mg and 20 mg tablets Administered as a once or twice daily regimen with total daily dose adjusted according to prevailing biochemistry

  • propylthiouracilDrug

    50 mg tablets administered once daily with the dose adjusted according to the prevailing biochemistry

  • thyroxineDrug

    25mcg, 50mcg and 100mcg tabletes administered once daily with the dose adjusted according to the prevailing biochemistry

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Biochemical control as reflected by the stability of blood thyroid stimulating hormone (TSH) concentrationsTime frame: 2.5 years

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Royal Aberdeen Children's Hospital

    Aberdeen, United Kingdom

  • Birmingham Children's Hospital

    Birmingham, United Kingdom

  • Addebrookes Hospital

    Cambridge, United Kingdom

  • Wales College of Medicine

    Cardiff, United Kingdom

  • University Hospital

    Coventry, United Kingdom

  • Ninewells Hospital

    Dundee, United Kingdom

  • Royal Hospital for Sick Children

    Edinburgh, United Kingdom

  • Royal Hospital for Sick Children

    Glasgow, United Kingdom

  • Hereford Hospital

    Hereford, United Kingdom

  • Crosshouse Hospital

    Kilmarnock, United Kingdom

  • Alder Hey Children's Hospital

    Liverpool, United Kingdom

  • St Bart's Hospital

    London, United Kingdom

  • St George's Hospital

    London, United Kingdom

  • Royal Manchester Children's Hospital

    Manchester, United Kingdom

  • Royal Victoria Infirmary

    Newcastle upon Tyne, United Kingdom

  • Norfolk & Norwich University Hospitals

    Norwich, United Kingdom

  • Oxford Radcliffe Hospitals

    Oxford, United Kingdom

  • Sheffield Children's Hospital

    Sheffield, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.